TurtleTree Becomes First to Receive FDA Clearance for Precision-Fermented Lactoferrin

TurtleTree, a biotech company based in California, has received FDA clearance for its precision fermentation-produced lactoferrin, known as LF+. The FDA's "No Questions" letter indicates that the agency has reviewed TurtleTree's Generally Recognized as Safe (GRAS) dossier and found no safety concerns, allowing the ingredient to be used in food products in the United States. This validation by the FDA is a significant moment for TurtleTree and the field of precision fermentation, according to CEO Fengru Lin.

LF+ is a bioactive milk protein with various health benefits, traditionally derived from bovine milk. TurtleTree's animal-free version of LF+ enables larger-scale production and potential applications in adult nutrition and functional foods. The FDA's clearance paves the way for TurtleTree to expand its market presence internationally, with regulatory submissions already underway in Europe and Asia. This approval removes regulatory uncertainties for manufacturers looking to incorporate LF+ into their products, supporting TurtleTree's efforts to bring this innovative ingredient to a wider consumer market.